Key Players
Competitive Landscape
The uterine serous carcinoma market brings together global checkpoint developers and HER2-directed oncology groups alongside targeted-therapy partners and clinical-stage biomarker specialists.
Investment has moved toward broader first-line access and biomarker-selected treatment development across endometrial cancer programs since 2025. In January 2025, GSK expanded the European Commission indication for dostarlimab plus chemotherapy to all adults with primary advanced or recurrent endometrial cancer. In June 2025, Daiichi Sankyo and AstraZeneca initiated the 600-participant DESTINY-Endometrial01 trial for HER2-expressing pMMR disease. Hospital committees now compare label breadth, biomarker fit and maintenance support across specialist formulary networks.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| GSK received expanded European Commission approval for dostarlimab plus chemotherapy, January 2025: MMRp/MSS tumors represent about 75% of endometrial cases. | Hospitals need first-line options across MMR groups. | Checkpoint labels extend beyond dMMR populations. | Induction and maintenance supply across European oncology centers. |
| Daiichi Sankyo and AstraZeneca initiated DESTINY-Endometrial01, June 2025: first participant dosed in a 600-participant Phase III study. | pMMR patients need alternatives to checkpoint-chemotherapy alone. | HER2-directed ADC combinations enter first-line Phase III testing. | HER2 testing, trial recruitment and future ADC supply. |
| Zentalis completed TETON Phase II enrollment, November 2025: Cyclin E1-positive advanced uterine serous carcinoma. | Cyclin E1-positive disease lacks a defined targeted regimen. | Small biomarker programs depend on focused capital and partnerships. | Licensing or co-development for Cyclin E1-selected treatment. |
Merck and Eisai compete through approved checkpoint and post-platinum routes, while Roche and Bristol Myers Squibb contribute exact-histology evidence or active endometrial research without separate January 2025 to present company developments in this section.
Source: Future Market Insights, Uterine Serous Carcinoma and Endometrial Cancer Treatment Market Reports, 2026-2036.
GSK and Merck cover broad first-line checkpoint regimens, while AstraZeneca and Daiichi Sankyo add dMMR and HER2-selected routes alongside Zentalis’s completed Cyclin E1-specific trial evidence.
Which companies hold the broadest first-line positions?
GSK and Merck hold the broadest first-line positions through all-comer checkpoint combinations supported by major regulatory or reimbursement decisions. AstraZeneca competes through a dMMR-specific durvalumab route that narrows eligibility but strengthens clinical biomarker fit.
Which companies support HER2-directed treatment?
Daiichi Sankyo and AstraZeneca sponsor first-line Phase III testing of trastuzumab deruxtecan combinations in HER2-expressing pMMR disease. Roche's trastuzumab has randomized Phase II evidence in HER2-positive uterine serous carcinoma within this exact histology.
Which companies have uterine serous carcinoma-specific evidence?
Zentalis completed TETON Phase II enrollment for Cyclin E1-positive advanced uterine serous carcinoma, although further development depends on partnering or available capital. Roche retains randomized trastuzumab evidence that directly covers HER2-positive uterine serous carcinoma within the exact histology.
Which companies cover first-line and post-platinum treatment?
Merck spans first-line pembrolizumab plus chemotherapy and post-platinum pembrolizumab with lenvatinib through its Eisai partnership. GSK and AstraZeneca focus on first-line combinations, while Eisai supplies the oral targeted component used after prior systemic therapy.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Merck & Co., Inc. | North America, Europe and Asia-Pacific | Pembrolizumab plus chemotherapy with maintenance; pembrolizumab-lenvatinib after prior systemic therapy. |
| GSK plc | North America, Europe and Asia-Pacific | Dostarlimab plus chemotherapy with maintenance; expanded European Commission indication (January 2025). |
| AstraZeneca PLC | North America, Europe and Asia-Pacific | Durvalumab for dMMR disease and co-development of DESTINY-Endometrial01. |
| Daiichi Sankyo Co., Ltd. | North America, Europe and Asia-Pacific | First participant dosed in DESTINY-Endometrial01 for HER2-expressing pMMR disease (June 2025). |
| Eisai Co., Ltd. | North America, Europe and Asia-Pacific | Lenvatinib with pembrolizumab after prior systemic therapy. |
| Roche Holding AG | North America | Trastuzumab supported by randomized Phase II uterine serous carcinoma evidence. |
| Bristol Myers Squibb Company | North America | Collaborator on an active investigator-led Phase II study of nivolumab with BMS-986205 in recurrent or persistent endometrial cancer. |
| Zentalis Pharmaceuticals, Inc. | North America | Azenosertib TETON Phase II evidence in Cyclin E1-positive advanced uterine serous carcinoma; further development depends on partnering or available capital. |
Research Methodology
The companies here show how the uterine serous carcinoma market is structured and do not form a revenue ranking. A company appears only where current evidence links an approved regimen, biomarker-selected program or exact-histology study to uterine serous carcinoma care. Evidence comes from regulatory decisions and trial registries alongside official company releases plus peer-reviewed studies that directly cover endometrial or uterine serous carcinoma. Regulatory access belongs to the named medicine and jurisdiction rather than every product within the wider corporate group. The 38.0% immunotherapy share remains an FMI estimate that applies to treatment modality demand in 2026.
